Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.
about
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCIs there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC.
P2860
Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@ast
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@en
type
label
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@ast
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@en
prefLabel
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@ast
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@en
P2093
P2860
P921
P356
P1433
P1476
Crizotinib versus platinum-bas ...... -positive lung adenocarcinoma.
@en
P2093
Jinghui Wang
Jingying Nong
Quan Zhang
Shucai Zhang
Xinjie Yang
Xinyong Zhang
P2860
P356
10.1111/1759-7714.12264
P577
2015-04-23T00:00:00Z